IFN-gamma-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands.
TLRs are key elements of the pathogen recognition mechanism used by the host immune system. Neutrophils express almost all TLRs, and activation of TLRs, such as TLR2 and TLR4, has been shown to induce the production of proinflammatory cytokines and chemokines, potentially linking innate and adaptive immunity. In the present study, we investigated whether activation of TLRs induces neutrophil production of MCP-1/CCL2, a key mediator involved in the development of adaptive immunity. Activation of neutrophils with LPS, lipoteichoic acid, or N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-Cys-[S]-Ser-[S]-Lys did not induce significant MCP-1 production and release; however, the Th1 cytokine IFN-gamma dramatically up-regulated MCP-1 production in cells activated with each TLR ligand. The majority of MCP-1 was released between 24 and 48 h of culture, indicating that this is a late event. The effect of IFN-gamma appeared to be due to its antiapoptotic effect, but not priming effect, revealing a biological consequence of IFN-gamma-induced neutrophil survival. Although IFN-gamma failed to protect neutrophils from cell death at a higher dose of LPS, the p38 MAPK inhibitor SB203580 dramatically increased MCP-1 release and neutrophil survival at this LPS concentration. Thus, p38 MAPK plays a previously uncharacterized role in neutrophil function. Taken together, our results indicate that human neutrophils produce MCP-1 in a Th1 microenvironment and this neutrophil-derived MCP-1 potentially amplifies the development of Th1 adaptive responses.
Yoshimura
Teizo
T
Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA. yoshimut@mail.nih.gov
Takahashi
Munehisa
M
D000942:Antigens, Bacterial / Q000502:physiology; D002470:Cell Survival / Q000276:immunology; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000096:biosynthesis* / Q000378:metabolism / Q000502:physiology; D006801:Humans; D007371:Interferon-gamma / Q000502:physiology*; D008024:Ligands; D008070:Lipopolysaccharides / Q000276:immunology; D018375:Neutrophil Activation / Q000276:immunology*; D009504:Neutrophils / Q000166:cytology* / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D051193:Toll-Like Receptors / Q000378:metabolism* / Q000502:physiology
D000942:Antigens, Bacterial; C111835:CCL2 protein, human; C515187:CXCR3 protein, human; D018932:Chemokine CCL2; D008024:Ligands; D008070:Lipopolysaccharides; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine; D018124:Receptors, Tumor Necrosis Factor; D051193:Toll-Like Receptors; D007371:Interferon-gamma